SNPMiner Trials (Home Page)
Report for Clinical Trial NCT01259050
Developed by Shray Alag, 2020-2021.
SNP Clinical Trial Gene
The purpose of this study is to determine the safety of Zinc given at 90mg/d in conjunction
with 2mg/d of copper in ALS patients.
Name: Zinc and Copper
Description: Optizinc 90 mg/d Copper 1 mg
Group Labels: 1 Zinc and Copper
Primary Outcomes Measure: To evaluate the safety of high doses of zinc in patients with ALS Time: 1 year
Secondary Outcomes Measure: Measure levels of BMAA in blood and urine to determine if there is a decline in these levels over the course of treatment Time: 1 year
Single Group Assignment
There is one SNP
Previous studies have shown that in ALS
mutant G93A SOD transgenic mice, actual zinc supplementation delayed death. --- G93A ---